<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CD4+ T cells play important roles in orchestrating host immune responses against <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">infectious diseases</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although EBV-encoded nuclear antigen 1-specific (EBNA1-specific) CD4+ T cells have been implicated in controlling the growth of EBV-associated <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> such as Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) in vitro, direct evidence for their in vivo function remains elusive due to the lack of an appropriate experimental <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> model </plain></SENT>
<SENT sid="2" pm="."><plain>Here, we describe the development of a mouse EBNA1-expressing <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model and the identification of 2 novel MHC H-2I-A(b)-restricted T cell <z:chebi fb="0" ids="53000">epitopes</z:chebi> derived from EBNA1 </plain></SENT>
<SENT sid="3" pm="."><plain>Using our murine <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> model and the relevant <z:chebi fb="7" ids="16670">peptides</z:chebi>, we show that vaccination of mice with EBNA1 <z:chebi fb="7" ids="16670">peptide</z:chebi>-loaded DCs can elicit CD4+ T cell responses </plain></SENT>
<SENT sid="4" pm="."><plain>These EBNA1-specific CD4+ T cells recognized <z:chebi fb="7" ids="16670">peptide</z:chebi>-pulsed targets as well as EBNA1-expressing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and were necessary and sufficient for suppressing <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>By contrast, EBNA1 <z:chebi fb="7" ids="16670">peptide</z:chebi>-reactive CD8+ T cells failed to recognize <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and did not contribute to protective immunity </plain></SENT>
<SENT sid="6" pm="."><plain>These studies represent what we believe to be the first demonstration that EBNA1-specific CD4+ T cells can suppress <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> in vivo, which suggests that CD4+ T cells play an important role in generating protective immunity against EBV-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>